These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Aortitis is an under-recognized manifestation of antiphospholipid syndrome: A case report and literature review. Escoda T; George J; Jarrot PA; Jean R; Mazodier K; Sanderson F; Poullin P; Saby L; Jourde-Chiche N; Kaplanski G; Chiche L Lupus; 2022 May; 31(6):744-753. PubMed ID: 35341372 [TBL] [Abstract][Full Text] [Related]
25. Rituximab use in the catastrophic antiphospholipid syndrome: descriptive analysis of the CAPS registry patients receiving rituximab. Berman H; Rodríguez-Pintó I; Cervera R; Morel N; Costedoat-Chalumeau N; Erkan D; Shoenfeld Y; Espinosa G; Autoimmun Rev; 2013 Sep; 12(11):1085-90. PubMed ID: 23777822 [TBL] [Abstract][Full Text] [Related]
26. Aortitis in the setting of catastrophic antiphospholipid syndrome in a patient with systemic lupus erythematosus. González-García A; López-Rodríguez M; Redondo S; Patier JL; Masso P; Tenorio M; Fajardo GS; Sarhane Y; Lacalzada MM; Manzano L Lupus; 2020 Aug; 29(9):1126-1129. PubMed ID: 32517572 [TBL] [Abstract][Full Text] [Related]
27. The diagnosis and clinical management of the catastrophic antiphospholipid syndrome: A comprehensive review. Cervera R; Rodríguez-Pintó I; Espinosa G J Autoimmun; 2018 Aug; 92():1-11. PubMed ID: 29779928 [TBL] [Abstract][Full Text] [Related]
32. Intravenous immunoglobulins and antiphospholipid syndrome: How, when and why? A review of the literature. Tenti S; Cheleschi S; Guidelli GM; Galeazzi M; Fioravanti A Autoimmun Rev; 2016 Mar; 15(3):226-35. PubMed ID: 26656906 [TBL] [Abstract][Full Text] [Related]
33. Diagnosis and management of catastrophic antiphospholipid syndrome. Carmi O; Berla M; Shoenfeld Y; Levy Y Expert Rev Hematol; 2017 Apr; 10(4):365-374. PubMed ID: 28277850 [TBL] [Abstract][Full Text] [Related]
34. Catastrophic antiphospholipid syndrome with concurrent thrombotic and hemorrhagic manifestations. Rangel ML; Alghamdi I; Contreras G; Harrington T; Thomas DB; Barisoni L; Andrews D; Wolf M; Asif A; Nayer A Lupus; 2013 Jul; 22(8):855-64. PubMed ID: 23722230 [TBL] [Abstract][Full Text] [Related]
35. Ferritin in the antiphospholipid syndrome and its catastrophic variant (cAPS). Agmon-Levin N; Rosário C; Katz BS; Zandman-Goddard G; Meroni P; Cervera R; Stojanovich L; Blank M; Pierangeli S; Praprotnik S; Meis Ed; Seguro LP; Ruffatti A; Pengo V; Tincani A; Doria A; Shoenfeld Y Lupus; 2013 Nov; 22(13):1327-35. PubMed ID: 24036580 [TBL] [Abstract][Full Text] [Related]
36. Update on the diagnosis, treatment, and prognosis of the catastrophic antiphospholipid syndrome. Cervera R Curr Rheumatol Rep; 2010 Feb; 12(1):70-6. PubMed ID: 20425537 [TBL] [Abstract][Full Text] [Related]
37. Eculizumab use in catastrophic antiphospholipid syndrome (CAPS): Descriptive analysis from the "CAPS Registry". López-Benjume B; Rodríguez-Pintó I; Amigo MC; Erkan D; Shoenfeld Y; Cervera R; Espinosa G; Autoimmun Rev; 2022 Apr; 21(4):103055. PubMed ID: 35085802 [TBL] [Abstract][Full Text] [Related]
38. Pediatric antiphospholipid syndrome: clinical features and therapeutic interventions in a single center retrospective case series. Madison JA; Gockman K; Hoy C; Tambralli A; Zuo Y; Knight JS Pediatr Rheumatol Online J; 2022 Feb; 20(1):17. PubMed ID: 35197077 [TBL] [Abstract][Full Text] [Related]